TickerFacts.

Tectonic Therapeutic, Inc. (TECX): Operating Income

Annual figures by period end, from SEC filings.

-$84.04M
Year ended 2025-12-31
-$94.92M
Trailing 12 months to 2026-06-30
2017-12-31: -$18.39M2018-12-31: -$46.24M2019-12-31: -$75.81M2020-12-31: -$120.23M2021-12-31: -$118.84M2022-12-31: -$105.43M2023-12-31: -$44.65M2024-12-31: -$58.02M2025-12-31: -$84.04M-$84.04M
2017-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$84.04Mn/m2026-02-26, From 2025-01-01
2024-12-31-$58.02Mn/m2026-02-26, From 2024-01-01
2023-12-31-$44.65Mn/m2025-03-20, From 2023-01-01
2022-12-31-$105.43Mn/m2024-03-14, From 2022-01-01
2021-12-31-$118.84Mn/m2023-03-23, From 2021-01-01
2020-12-31-$120.23Mn/m2022-03-17, From 2020-01-01
2019-12-31-$75.81Mn/m2021-03-18, From 2019-01-01
2018-12-31-$46.24Mn/m2020-03-16, From 2018-01-01
2017-12-31-$18.39Mn/a2019-03-25, From 2017-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Tectonic Therapeutic, Inc. (TECX)2025-12-31-$84.04Mn/m
Coherus Oncology, Inc. (CHRS)2025-12-31-$181.13Mn/m
Lexeo Therapeutics, Inc. (LXEO)2025-12-31-$109.26Mn/m
Voyager Therapeutics, Inc. (VYGR)2025-12-31-$131.84Mn/m
Invivyd, Inc. (IVVD)2025-12-31-$55.56Mn/m
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31-$68.76Mn/m
MeiraGTx Holdings plc (MGTX)2025-12-31-$105.97Mn/m
X4 Pharmaceuticals, Inc (XFOR)2025-12-31-$86.88Mn/m
DBV Technologies S.A. (DBVT)2025-12-31-$147.06Mn/m

Compare TECX, CHRS, LXEO, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗